Novozymes (0Q4U) Stock Overview

Produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. More details

0Q4U fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	4/6
Financial Health	5/6
Dividends	3/6

Rewards

Trading at 32.7% below our estimate of its fair value

Earnings are forecast to grow 13.75% per year

Earnings have grown 5.9% per year over the past 5 years

Risk Analysis

No risks detected for 0Q4U from our risk checks.

0Q4U Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW443,467 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

443,467 investors already sharing narratives

View all narratives

Novozymes A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novozymes
Historical stock prices
Current Share Price	DKK 429.40
52 Week High	DKK 464.50
52 Week Low	DKK 337.50
Beta	0.63
1 Month Change	1.74%
3 Month Change	13.51%
1 Year Change	6.96%
3 Year Change	43.85%
5 Year Change	-10.13%
Change since IPO	354.00%

Recent updates

Shareholder Returns

	0Q4U	GB Chemicals	GB Market
7D	-1.8%	-1.6%	-1.8%
1Y	7.0%	11.0%	15.2%

Return vs Industry: 0Q4U underperformed the UK Chemicals industry which returned 11% over the past year.

Return vs Market: 0Q4U underperformed the UK Market which returned 15.2% over the past year.

Price Volatility

Is 0Q4U's price volatile compared to industry and market?
0Q4U volatility
0Q4U Average Weekly Movement	3.9%
Chemicals Industry Average Movement	6.5%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.5%

Stable Share Price: 0Q4U has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0Q4U's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	11,098	Ester Baiget	www.novonesis.com

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel.

Novozymes A/S Fundamentals Summary

How do Novozymes's earnings and revenue compare to its market cap?
0Q4U fundamental statistics
Market cap	DKK 200.06b
Earnings (TTM)	DKK 4.72b
Revenue (TTM)	DKK 32.13b

42.4x

P/E Ratio

6.2x

P/S Ratio

Is 0Q4U overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0Q4U income statement (TTM)
Revenue	€4.30b
Cost of Revenue	€1.87b
Gross Profit	€2.42b
Other Expenses	€1.79b
Earnings	€631.60m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Nov 05, 2026

Earnings per share (EPS)	1.36
Gross Margin	56.39%
Net Profit Margin	14.70%
Debt/Equity Ratio	25.8%

How did 0Q4U perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

65%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/14 03:10
End of Day Share Price	2026/09/14 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novozymes A/S is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Cezara Lozneanu	Barclays
Alexander Sloane	Barclays
Sebastian Satz	Barclays

Novozymes (0Q4U) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Novozymes A/S Competitors

Croda International

Elementis

Fresnillo

Antofagasta

Price History & Performance

Recent News & Updates

Novozymes A/S to Report Fiscal Year 2026 Results on Feb 11, 2027

First half dividend of kr.2.35 announced

Novonesis A/S Approves Interim Dividend for the First Six Months of 2026, Payable on August 27, 2026

Novozymes A/S (CPSE:NSIS B) announces an Equity Buyback for €1,000 million worth of its shares.

Second quarter 2026 earnings released: EPS: €0.37 (vs €0.29 in 2Q 2025)

Novonesis Launches Optiva Triticum to Help Pasta Manufacturers Navigate Wheat Volatility Without Compromising Quality

Recent updates

Novozymes A/S to Report Fiscal Year 2026 Results on Feb 11, 2027

First half dividend of kr.2.35 announced

Novonesis A/S Approves Interim Dividend for the First Six Months of 2026, Payable on August 27, 2026

Novozymes A/S (CPSE:NSIS B) announces an Equity Buyback for €1,000 million worth of its shares.

Second quarter 2026 earnings released: EPS: €0.37 (vs €0.29 in 2Q 2025)

Novonesis Launches Optiva Triticum to Help Pasta Manufacturers Navigate Wheat Volatility Without Compromising Quality

Novozymes A/S (CPSE:NSIS B) signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd.

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Novonesis A/S Approves Dividend on A and B Share

Upcoming dividend of kr.4.25 per share

Vice Chair of the Board recently bought kr.1.0m worth of stock

Full year 2025 earnings released: EPS: €1.25 (vs €1.10 in FY 2024)

Dividend of kr.4.25 announced

Vice Chair of the Board recently bought kr.1.0m worth of stock

Novozymes A/S, Annual General Meeting, Mar 23, 2026

Novozymes A/S Proposes Dividend for Full Year 2025

Now 22% overvalued

Now 21% overvalued

Now 22% overvalued after recent price rise

Third quarter 2025 earnings released: EPS: €0.29 (vs €0.33 in 3Q 2024)

Novozymes A/S Revises Earnings Guidance for the Year 2025

Vice Chair of the Board recently bought kr.1.2m worth of stock

First half dividend of kr.2.25 announced

Novonesis A/S Approves Interim Dividend for First Half of 2025

Now 20% undervalued after recent price drop

New major risk - Revenue and earnings growth

Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).

First quarter 2025 earnings released: EPS: €0.40 (vs €0.08 in 1Q 2024)

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Now 21% undervalued after recent price drop

Less than half of directors are independent

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Novonesis A/S Announces Board Changes

Full year 2024 earnings released: EPS: €0.67 (vs €1.46 in FY 2023)

Novonesis A/S Proposes Dividend, Payable on April 8, 2025

Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025

Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Now 10% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 22% overvalued after recent price rise

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Financial position

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Now 21% undervalued after recent price drop

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023